Haemonetics Corp. (HAE) Tops Q4 EPS by 2c, Announces Buyback Plan and Posts FY12 Guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $90.38 -0.46%
Financial Fact:
Operating income: 24.79M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Operating income: 24.79M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q4 adjusted EPS of $0.85, $0.02 better than the analyst estimate of $0.83. Revenue for the quarter came in at $170 million versus the consensus estimate of $180.31 million.
Haemonetics Corp. sees FY2012 EPS of $3.50-$3.62, versus the consensus of $3.56. Haemonetics announced its fiscal 2012 annual guidance for organic revenue growth of 4-6%.
he Company announced that its Board of Directors has approved a $50 million share repurchase.
Haemonetics Corp. sees FY2012 EPS of $3.50-$3.62, versus the consensus of $3.56. Haemonetics announced its fiscal 2012 annual guidance for organic revenue growth of 4-6%.
he Company announced that its Board of Directors has approved a $50 million share repurchase.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
- Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
Create E-mail Alert Related Categories
Earnings, Guidance, Stock BuybacksRelated Entities
Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
